From Name:
From Email:
To Name:
To Email:

Optional Message:

Cangrelor Alone Reduces Bleeding Risk Compared With Clopidogrel and GPIs

from The Cardiology Advisor

In an exploratory analysis of the CHAMPION (Cangrelor vs Standard Therapy to Achieve Optimal Management of Platelet Inhibition) trials, cangrelor was found to have a similar ischemic risk and reduced bleeding risk compared with clopidogrel glycoprotein IIb/IIIa inhibitors. The researchers, led by Deepak L. Bhatt, MD, MPH, of Brigham and Women's Hospital Heart & Vascular Center in Boston, sought to compare these risks between the two treatments in patients undergoing percutaneous coronary intervention. more

Powered by MultiBriefs
7701 Las Colinas Blvd., Ste. 800, Irving, TX 75063